The clinical presentation of AA amyloidosis is dependent on which organ systems are affected. The kidneys are affected the majority of the time (90% of the time), and untreated AA amyloidosis can lead to end-stage renal disease. The liver and heart are other major sites of amyloid deposition. Gastrointestinal (GI) amyloidosis is also more common in AA amyloidosis, present in 10%-70% of patients depending on series.
Signs and symptoms of AA amyloidosis include arrhythmia, dysphagia, dyspnea, anasarca, fatigue, numbness in hands and feet, rash, easy bruising, swollen tongue or uvula, weak grip, weight loss, diarrhea, GI tract bleeding, proteinuria, hepatomegaly, and splenomegaly.
The hallmark of treatment for AA amyloidosis is treating the underlying inflammatory disease process.
Related topic: AL amyloidosis
E85.3 – Secondary systemic amyloidosis
402457007 – Secondary systemic amyloidosis affecting skin (AA fibril type)
- AL amyloidosis
- Hereditary amyloidosis
- Dialysis-related amyloidosis
- Age-related systemic amyloidosis
- Diabetic nephropathy
- Membranoproliferative glomerulonephritis
- Membranous nephropathy
- Focal segmental glomerulosclerosis
- Fibrillary glomerulonephritis
- Idiopathic nodular glomerulosclerosis
- Ischemic cardiomyopathy (see dilated cardiomyopathy)
- Systemic lupus erythematosus
- Multiple myeloma